EPAX® Norwegian High-Concentration Omega-3 Fish Oil (Condition-Specific EPA/DHA Concentrates & NovusLipid™)

INGREDIENT PROFILE

What this ingredient is documented for

Origin

Norway

Developer

Epax Norway AS, Ålesund, Norway (a wholly owned subsidiary of Pelagia AS)

• A marine-lipid specialist based in Ålesund, Norway and wholly owned by Pelagia AS, with a heritage tracing back to 1838 (JC Martens, Bergen) and credited with commercialising the first omega-3 concentrates in 1986; today around 80 employees, 19 off-the-shelf grades and more than 100 peer-reviewed clinical studies behind the brand
• Ultra concentrates (min. 700 mg/g total EPA+DHA): EPAX® 4832 TGN (480 mg/g EPA / 320 mg/g DHA), 5025 TGN (500/250), 2050 TGN (205/500), 6015 TGN (530/100) and 4030 TGN/EE (400/300); supplied as rTG (re-esterified triglyceride, min. 90% TG content) or EE, with custom EPA/DHA ratios available from 50 to 800 mg/g
• Core concentrates (up to 699 mg/g total EPA+DHA) for condition-specific formulation — cardiovascular, brain and cognition, eye health, maternal and infant nutrition: EPAX® 0460 TGN (40/600, high-DHA), 1500 TGN/EE (105/500), 4020 TGN/EE (400/200), 3624 TGN/EE (360/240), 6000 TGN/EE (300/200) and 4717 EE (470/180)
• EPAX® NovusLipid™ — next-generation marine lipids beyond conventional omega-3: EPAX® Evolve 05 is patent-protected and the world’s first commercially available VLC-PUFA oil (min. 50 mg/g VLC-PUFA, min. 400 mg/g omega-3), addressing the age-related decline of the ELOVL2 enzyme for eye, cognitive, skin, reproductive and metabolic health; EPAX® Omega 3-9-11 supplies LC-MUFAs (300 mg/g cetoleic, 90 mg/g gondoic) alongside 50 mg/g EPA and 200 mg/g DHA
• Quality and sustainability: pharma-compliant, cGMP and FDA-inspected production with very low environmental and oxidative impurities and, per the manufacturer, no product recall in its history; certifications include FSSC 22000, GMP, ISO 14001, Friend of the Sea and MarinTrust chain of custody, and Halal; a vertically integrated, fully traceable supply chain operating on 100% hydropower with 97% circularity for biomaterials under the EPAX® EcoVision framework